Skip to main content
GC CELL CORPORATION logo

GC CELL CORPORATION — Investor Relations & Filings

Ticker · 144510 ISIN · KR7144510005 KO Manufacturing
Open in API
Filings indexed 262 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 144510

About GC CELL CORPORATION

http://gccell.com/en/main.do

GC CELL CORPORATION specializes in cell and gene therapy, providing a fully integrated value chain from research to commercialization. The company's core offerings include end-to-end Contract Development and Manufacturing Organization (CDMO) services for autologous and allogeneic cell therapies, comprehensive bio-logistics, and cell banking. Its integrated model supports partners throughout the entire drug life cycle, from initial development and manufacturing to clinical trials and commercial distribution. In addition to its service-based solutions, GC CELL develops proprietary cell therapy products, including Immuncell-LC, an adjuvant therapy for hepatocellular carcinoma. The company focuses on advancing treatments in areas such as immune-oncology and delivering customized solutions to enhance patient outcomes.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean statutory quarterly report (“분기보고서”) covering the period Jan 1 to Mar 31 2026, complete with detailed business overview, segment performance, financial tables, risk disclosures, etc. It is not merely an announcement or certification but the full interim/quarterly filing itself. This corresponds exactly with the “Interim / Quarterly Report” category. Q1 2026
2026-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Interim / Quarterly Report Classification · 95% confidence The document is a preliminary (잠정) earnings report for the first quarter of 2026, showing consolidated financial results including sales, operating profit, and net income. It explicitly states that the figures are provisional and subject to change after external audit review. The document includes detailed financial data for the quarter and comparisons to previous periods. The length is 2476 characters, which is relatively short but contains substantive financial data, not just an announcement or a certification. The content matches the characteristics of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year with actual financial figures and analysis. Therefore, the correct classification is IR with high confidence. Q1 2026
2026-05-07 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is the formal announcement of the results of the company’s Annual General Meeting held on 2026-03-24, detailing the resolutions passed, vote percentages, and related matters. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-03-24 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 99% confidence The document is a comprehensive 'Audit Report' (감사보고서) for GC Cell (주식회사 지씨셀) for the fiscal year ending December 31, 2025. It includes the independent auditor's report, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. While it contains financial data, it is a formal audit report rather than a full 10-K annual report (which would include management discussion and analysis, business overview, etc.) or a simple earnings release. Therefore, it is classified as an Audit Report. FY 2025
2026-03-16 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It contains detailed financial tables including consolidated and separate financial statements, audit opinions, and financial ratios for the fiscal year ending 2025-12-31. While it provides financial data, it is a structured regulatory disclosure of the audit results rather than the full Annual Report (10-K) or a simple announcement of report publication (RPA). Given the specific nature of audit report submissions in the Korean market, it falls under the category of Audit Report / Information. FY 2025
2026-03-16 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a correction (정정신고) to a previously filed 'Change in Sales or Profit/Loss Structure' report. It details specific financial adjustments made during the external audit process, including updated figures for net income and assets. Since this is a formal regulatory disclosure of financial performance changes rather than a full annual report or a simple announcement of a report's availability, it falls under the category of general regulatory filings.
2026-03-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.